Literature DB >> 8368464

A comparison of the efficacy of cetirizine and terfenadine. A double-blind, controlled study of chronic idiopathic urticaria.

L Andri1, G E Senna, C Betteli, S Givanni, G Andri, C Lombardi, P Mezzelani.   

Abstract

In a 20-d, double-blind, randomized, parallel study, the efficacy of cetirizine and terfenadine was compared in 30 patients with chronic idiopathic urticaria. Subjects were randomly divided into two 15-patient groups. The first group was given cetirizine (10 mg once daily); the second terfenadine (60 mg twice daily). Cetirizine proved to be more effective than terfenadine in controlling urticaria symptoms. In fact, the score of the investigators' overall assessment was significantly lower in the cetirizine-treated group than in the terfenadine-treated group. Moreover, patient evaluation by a visual analog scale and symptoms assessed on a 4-point scale showed a better improvement in the cetirizine group. The number and severity of side-effects were similar in both treatment groups.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8368464     DOI: 10.1111/j.1398-9995.1993.tb02406.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  4 in total

1.  A STUDY ON TREATMENT OF CHRONIC IDIOPATHIC URTICARIA WITH CETIRIZINE.

Authors:  P K Kar; Kvr Chari
Journal:  Med J Armed Forces India       Date:  2017-06-26

Review 2.  New insights into the second generation antihistamines.

Authors:  G M Walsh; L Annunziato; N Frossard; K Knol; S Levander; J M Nicolas; M Taglialatela; M D Tharp; J P Tillement; H Timmerman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Cetirizine: a review of its use in allergic disorders.

Authors:  Monique P Curran; Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 4.  Urticaria. Recognition, causes and treatment.

Authors:  A D Ormerod
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.